Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ATI stock jumps 45% in three months as aerospace demand, engine content growth and strategic CapEx lift prospects, while strong cash flow and earnings outlook support momentum.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Five of the portfolio's 10 equity sectors made a positive impact on performance in 2025, with Industrials, IT, and Financials making the largest positive contributions, while Consumer Discretionary, Energy, and Consumer Staples had the biggest negative effect. Our top contributor at the holdings level was nLIGHT, whose shares have outperformed due to upward revisions to the outlook for its aerospace & defense customers. The Fund's top-detracting position was Lakeland Industries.
Here is how ATI (ATI) and AAR (AIR) have performed compared to their sector so far this year.
ATI (ATI) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ATI (ATI) reported earnings 30 days ago. What's next for the stock?
ATI (ATI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Does ATI (ATI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded its biosimilars portfolio and strengthened its generics business, returning that segment to positive growth.
ATI launches new $500M buyback, signaling confidence in aerospace demand, cash flow and long-term earnings growth.